Catalyst Biosciences announces proposed public offering of common stock
Catalyst Biosciences announced it is offering shares of its common stock in an underwritten public offering. The Company anticipates using net proceeds from this offering for general corporate purposes, which may include clinical and manufacturing activities for CB 2679d. February 12, 2018